Coston McIsaac & Partners’s ResMed RMD Stock Holding History

Coston McIsaac & Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38K	Hold	196	–	–	0.01%	380
2026 Q1	$43K	Hold	196	–	–	0.01%	345
2025 Q4	$47K	Hold	196	–	–	0.01%	329
2025 Q3	$53K	Hold	196	–	–	0.01%	296
2025 Q2	$50K	Hold	196	–	–	0.01%	296
2025 Q1	$43K	Hold	196	–	–	0.01%	294
2024 Q4	$44K	Hold	196	–	–	0.01%	297
2024 Q3	$47K	Hold	196	–	–	0.01%	291
2024 Q2	$37K	Hold	196	–	–	0.01%	310
2024 Q1	$38K	Hold	196	–	–	0.01%	313
2023 Q4	$33K	Hold	196	–	–	0.01%	328
2023 Q3	$28K	Hold	196	–	–	0.01%	334
2023 Q2	$42K	Hold	196	–	–	0.01%	298
2023 Q1	$42K	Hold	196	–	–	0.02%	290
2022 Q4	$40K	Hold	196	–	–	0.02%	307
2022 Q3	$42K	Hold	196	–	–	0.02%	238
2022 Q2	$41K	Buy	+196	New	+$41.7K	0.02%	150

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Coston McIsaac & Partners's RMD Position: Q2 2026 in Review

Coston McIsaac & Partners held its ResMed (RMD) position steady in Q2 2026 at 196 shares worth $38K. The position accounts for 0.01% of the portfolio, ranked #380.

Coston McIsaac & Partners first reported a position in RMD in Q2 2022 and has held it in 17 quarters since. The position peaked at $53K in Q3 2025. 885 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Coston McIsaac & Partners held 196 shares of ResMed worth $38K as of Q2 2026.
Coston McIsaac & Partners left its ResMed share count unchanged in Q2 2026.
ResMed made up 0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #380 holding.
Coston McIsaac & Partners first reported a position in ResMed in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's ResMed position peaked at $53K in Q3 2025.
885 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.